%0 Journal Article
%T Prospective comparison of cytomegalovirus quantification in whole blood and plasma samples among hematopoietic stem cell transplant and kidney transplant recipients.
%A Helary M
%A Schnepf N
%A Mahjoub N
%A Lacroix M
%A Xhaard A
%A Divard G
%A Delaugerre C
%A Biard L
%A LeGoff J
%A Feghoul L
%J J Clin Virol
%V 174
%N 0
%D 2024 May 13
%M 38852538
%F 14.481
%R 10.1016/j.jcv.2024.105690
%X <B>BACKGROUND: </B>Cytomegalovirus (CMV) induces multi-organ pathogenesis in hematopoietic stem cell transplant (HSCT) and kidney transplant (KT) recipients. Effective management involves systematic monitoring for CMV reactivation by quantitative real-time PCR, allowing timely preemptive intervention. However, the optimal blood compartment for CMV surveillance remains undetermined.<BR><B>OBJECTIVE: </B>The aim of the study was to compare the quantification of CMV DNA in paired plasma and whole blood samples.<BR><B>METHODS: </B>From June and October 2022, we conducted a prospective study with 390 sets of paired plasma and whole blood specimens collected from 60 HSCT and 24 KT recipients. CMV DNA levels were compared between the cobas® CMV assay on the automated cobas® 6800 system for plasma and the reference assay, Abbott RealTime CMV assay on the m2000 RealTime platform for whole blood.<BR><B>RESULTS: </B>The sensitivity and specificity of CMV quantification in plasma using the cobas® CMV assay were 90.0 % (95 %CI: 81.5 to 95.9) and 94.8 % (95 %CI: 91.8 to 96.8), respectively, compared to whole blood quantification with the Abbott assay. The overall agreement between these two strategies was 0.89 (95 %CI: 0.86-0.91). In samples with quantifiable results, a correlation was observed between the two methods (R2 = 0.62, 95 %CI: 0.65-0.87, p < 0.0001). CMV loads were significantly higher in whole blood, with a mean bias of 0.42 log10 IU/mL (95 %CI: -0.32-1.15).<BR><B>CONCLUSIONS: </B>The cobas® CMV assay in plasma showed significant concordance with the Abbott RealTime CMV assay in whole blood, confirming the relevance of plasma samples for CMV monitoring in HSCT and KT recipients.